Top Markets
#1 Purr Purr +61.35%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +40.06%
#4 Kinetiq Kinetiq +32.46%
#5 Non-Playable Coin Non-Playable Coin +25.26%
#6 ApeX ApeX +23.78%
#7 OriginTrail OriginTrail +19.68%
#8 Pudgy Penguins Pudgy Penguins +19.22%
#9 Morpho Morpho +18.78%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.80%
Coin of the day
Purr Purr
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA
Classifica tra le azioni #21166
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Prezzo delle azioni
$4.83
Ultima sincronizzazione: 2026-08-21
Capitalizzazione di mercato
$113.30M
Variazione (1 giorno)
-0.62%
Variazione (1 anno)
-29.59%
Paese
US
Scambia Coya Therapeutics, Inc. (COYA)

Categoria

Healthcare
Numero di azioni in circolazione per Coya Therapeutics, Inc. (COYA)
Numero di azioni in circolazione al August 2026: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Coya Therapeutics, Inc., il numero attuale di azioni in circolazione è 0. Alla fine del August 2026, la società aveva 0 azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Coya Therapeutics, Inc. (COYA) dal 2026 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
Non abbastanza dati per le date fornite.
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH